TXG Price Prediction Next Week
Analysis and Insights
News and Sentiment Analysis:
- Citi's Price Target Adjustment: Citi has reduced the price target for 10x Genomics (TXG) from $20 to $15 while maintaining a Buy rating, citing light investor interest in the life sciences sector due to U.S. government pressures.
- Insider Trading Activity: Serge Saxonov, CEO of TXG, sold 7,942 shares, representing about 0.9% of his holdings, leaving him with 871,540 shares. In the past six months, there have been 5 sales and 1 purchase by insiders.
- Institutional Investor Movements: In the latest quarter, 131 institutional investors increased their positions in TXG stock while 181 decreased theirs, indicating mixed sentiment among large shareholders.
- Market Capitalization Drop: The market capitalization required for companies to join the Russell 2000 Index has decreased by 12% to $129M due to a decline in stock performance, with the index falling 9.4% recently compared to a smaller drop in the Russell 1000 index.
Technical Analysis:
- Current Price: $9.959999999999999
- RSI (14): 37.77 (Oversold)
- MACD: -0.68 (Bearish)
- Bollinger Bands: Price is near the lower band, indicating potential oversold conditions.
- Fibonacci Levels:
- Resistance: $11.48
- Support: $9.52
Price Prediction:
Based on the oversold RSI and proximity to the Fibonacci support level, TXG is likely to experience a short-term bounce. However, considering the overall negative sentiment and sector challenges, the upside is limited.
Predicted Price for Next Trading Week: $10.50
Recommendation:
Sell if the price reaches $10.50, as the broader market and sector challenges may weigh on the stock's ability to sustain higher levels.
TXG Similar Chart Price Prediction
The price of TXG is predicted to go up 2.16%, based on the high correlation periods with TPC. The similarity of these two price pattern on the periods is 97.52%.
TXG
TPC
Up: 2.16%Similarity: 97.52%
TXG Revenue Forecast
TXG EPS Forecast
TXG FAQs
What is TXG revenue forecast for next quarter？
TXG Analyst's Forecast
Patrick Donnelly
Citigroup
Strong Buy
2025-03-04
Price Target
$20 → $15
Upside
+42.59%
Citi lowered the firm's price target on 10x Genomics to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the life science tools and diagnostics group post the Q4 reports. Coming away from earnings, investor appetite for the sector "remains very light," primarily due to ongoing U.S. government pressure, the analyst tells investors in a research note. However, Citi sees pockets of the market to be constructive on, such as bioprocessing, where it believes a recovery is underway. Danaher (DHR) is the firm's top pick.
Tejas Savant
Morgan Stanley
Buy
2025-02-14
Price Target
$28 → $26
Upside
+111.12%
Luke Sergott
Barclays
Buy
2025-02-14
Price Target
$18 → $15
Upside
+21.8%
